Blocking LAG-3, but not PD-L1/PD-1 pathway, enhanced T cell activation in patients with CLL, making LAG-3 a potential target to treat CLL [108]. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.